Apellis Pharmaceuticals (NASDAQ:APLS) Given Buy Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Apellis Pharmaceuticals (NASDAQ:APLS) in a report released on Friday, Benzinga reports. The firm currently has a $92.00 target price on the stock.

Other equities research analysts have also recently issued research reports about the company. UBS Group upped their target price on Apellis Pharmaceuticals from $87.00 to $89.00 and gave the stock a buy rating in a research report on Monday, March 4th. Needham & Company LLC reaffirmed a buy rating and set a $85.00 target price on shares of Apellis Pharmaceuticals in a research report on Thursday. Robert W. Baird reaffirmed an outperform rating and set a $81.00 target price on shares of Apellis Pharmaceuticals in a research report on Tuesday, February 6th. Wedbush decreased their target price on Apellis Pharmaceuticals from $67.00 to $57.00 and set a neutral rating for the company in a research report on Wednesday, April 17th. Finally, JPMorgan Chase & Co. upped their target price on Apellis Pharmaceuticals from $78.00 to $79.00 and gave the stock an overweight rating in a research report on Wednesday, March 6th. Three research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of Moderate Buy and an average target price of $77.93.

Apellis Pharmaceuticals Trading Up 4.0 %

NASDAQ:APLS opened at $49.86 on Friday. The stock’s 50 day moving average price is $57.84 and its 200 day moving average price is $57.35. Apellis Pharmaceuticals has a 52 week low of $19.83 and a 52 week high of $94.75. The company has a market capitalization of $6.01 billion, a P/E ratio of -11.13 and a beta of 0.88. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.50 and a current ratio of 3.10.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its quarterly earnings data on Tuesday, February 27th. The company reported ($0.73) EPS for the quarter, hitting analysts’ consensus estimates of ($0.73). Apellis Pharmaceuticals had a negative return on equity of 178.60% and a negative net margin of 133.34%. The firm had revenue of $146.38 million for the quarter, compared to the consensus estimate of $143.34 million. During the same quarter in the prior year, the company posted ($1.50) earnings per share. The firm’s revenue was up 545.9% on a year-over-year basis. On average, research analysts forecast that Apellis Pharmaceuticals will post -1.33 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Pascal Deschatelets sold 69,107 shares of the firm’s stock in a transaction on Monday, April 8th. The stock was sold at an average price of $54.17, for a total value of $3,743,526.19. Following the completion of the transaction, the insider now directly owns 1,115,983 shares of the company’s stock, valued at $60,452,799.11. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, insider Pascal Deschatelets sold 69,107 shares of the firm’s stock in a transaction on Monday, April 8th. The stock was sold at an average price of $54.17, for a total value of $3,743,526.19. Following the completion of the transaction, the insider now directly owns 1,115,983 shares of the company’s stock, valued at $60,452,799.11. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Mark Jeffrey Delong sold 9,913 shares of the firm’s stock in a transaction on Monday, March 18th. The stock was sold at an average price of $56.90, for a total value of $564,049.70. Following the completion of the transaction, the insider now directly owns 54,693 shares of the company’s stock, valued at $3,112,031.70. The disclosure for this sale can be found here. Insiders sold a total of 381,011 shares of company stock valued at $23,463,657 over the last ninety days. 7.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. First Horizon Advisors Inc. raised its stake in Apellis Pharmaceuticals by 69.0% during the third quarter. First Horizon Advisors Inc. now owns 649 shares of the company’s stock worth $25,000 after acquiring an additional 265 shares in the last quarter. Future Financial Wealth Managment LLC acquired a new position in Apellis Pharmaceuticals during the first quarter worth $29,000. Covestor Ltd raised its stake in Apellis Pharmaceuticals by 564.2% during the third quarter. Covestor Ltd now owns 797 shares of the company’s stock worth $30,000 after acquiring an additional 677 shares in the last quarter. Stephens Consulting LLC acquired a new position in Apellis Pharmaceuticals during the third quarter worth $38,000. Finally, China Universal Asset Management Co. Ltd. raised its stake in Apellis Pharmaceuticals by 29.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 3,028 shares of the company’s stock worth $115,000 after acquiring an additional 687 shares in the last quarter. 96.29% of the stock is currently owned by institutional investors and hedge funds.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).